Results 81 to 90 of about 183,958 (171)

Tolerance of Concurrent Adjuvant Radiation Therapy and Pembrolizumab for Triple Negative Breast Cancer: Real Life Experience

Advances in Radiation Oncology
Purpose: The current standard-of-care management of locally advanced triple negative breast cancer (TNBC) is based on neoadjuvant chemo-immunotherapy with pembrolizumab, surgery, radiation therapy (RT), and adjuvant pembrolizumab.
Thais Tison, MD, Pierre Loap, MD, Emilie Arnaud, MD, Kim Cao, MD, Solene Bringer, MD, Manon Kissel, MD, Safia Maaradji, MD, Juliette Mainguene, MD, Jean-Yves Pierga, MD, PhD, Florence Lerebours, MD, Anne Vincent-Salomon, MD, PhD, Mariana Mirabelle, MD, Francois-Clement Bidard, MD, PhD, Delphine Loirat, MD, PhD, Youlia M. Kirova, MD   +14 more
doaj   +1 more source

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

BMC Cancer
Background Immunotherapy-based combinations have emerged as standard therapies for patients with metastatic renal cell carcinoma (mRCC). Pembrolizumab, a PD-1 inhibitor, combined with epacadostat, an indoleamine 2,3-deoxygenase 1 selective inhibitor ...
Primo N. Lara, Luis Villanueva, Carolina Ibanez, Mustafa Erman, Jae Lyun Lee, Daniel Heinrich, Oleg Nikolaevich Lipatov, Craig Gedye, Erhan Gokmen, Alejandro Acevedo, Andrey Semenov, Se Hoon Park, Rustem Airatovich Gafanov, Fatih Kose, Mark Jones, Xiaoqi Du, Mihaela Munteanu, Rodolfo Perini, Toni K. Choueiri, Robert J. Motzer   +19 more
doaj   +1 more source

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

BMC Cancer
Background Indoleamine 2,3-dioxygenase 1 (IDO1) levels correlate with poor outcomes in urothelial carcinoma (UC). IDO1 and programmed death-ligand 1 (PD-L1) are often co-expressed. Epacadostat is a potent and highly selective inhibitor of IDO1.
Irfan Cicin, Elizabeth R. Plimack, Howard Gurney, Raya Leibowitz, Boris Y. Alekseev, Francis X. Parnis, Avivit Peer, Andrea Necchi, Joaquim Bellmunt, Hiroyuki Nishiyama, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Thomas Powles, Cora N. Sternberg   +15 more
doaj   +1 more source

Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer

Journal for ImmunoTherapy of Cancer
Intravenous immune checkpoint inhibition achieves a 40% 3-month response in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.
Joshua J Meeks, Khyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy   +4 more
doaj   +1 more source

SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. [PDF]

, 2019
BACKGROUND:Programmed cell death ligand-1 (PD-L1) expression on tumor cells (TCs) is associated with improved survival in patients with head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy, although its role as a prognostic factor is ...
Baste, Neus, Clayburgh, Daniel, Cohen, Ezra EW, Fountzilas, George, Fujii, Takashi, Khaliq, Asud, Kim, Edward S, Lin, Derrick, Lipworth, Loren, Mehlhorn, Holger, Melillo, Giovanni, Pai, Sara I, Resteghini, Carlo, Shara, Nawar, Shire, Norah, Stokes, Michael, Twumasi-Ankrah, Philip, Wang, Huifen, Wildsmith, Sophie, Zhang, Jun   +19 more
core   +1 more source

Cost-effectiveness analysis of pembrolizumab versus chemotherapy in advanced non-small cell lung cancer in China based on real-world studies

Journal of Cancer Research and Clinical Oncology
Background Although pembrolizumab has been shown to be effective, its high price has prevented it from being widely used. Especially in the real world, the application situation is still uncertain.
Ning Wan, Chen Yang, Bing Wang, Ya Guo, ZiJian He, YaJuan Lv, LiQing Lu, Ning Yang, WeiBin Xiao, YongBang Chen, Jin Yuan, DanDan Yang, Tao Liu, WenFeng Fang, ZhuoJia Chen, WeiTing Liang   +15 more
doaj   +1 more source

A case of severe visual loss related to treatment with pembrolizumab for metastatic renal pelvic cancer

IJU Case Reports
Introduction Pembrolizumab is the standard therapy for urothelial carcinoma treatment; however, adverse events have been noted. Here, we report a rare case of vision loss as an immune‐related adverse event of pembrolizumab therapy in a patient with ...
Naoki Inoue, Mihoko Iitzuka, Hiroki Tanaka, Yudai Ishikawa, Naoko Kawamura, Tetsuo Okuno   +5 more
doaj   +1 more source

Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome [PDF]

, 2018
Stevens-Johnson syndrome is a rare adverse cutaneous drug reaction characterized by epidermal detachment of
Al-Omari, Ahmed, Rancour, Elizabeth A., Shah, Kishan M.   +2 more
core  

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. [PDF]

, 2019
PurposeGlioblastoma (GBM) remains an incurable disease despite extensive treatment with surgical resection, irradiation, and temozolomide. In line with many other forms of aggressive cancers, GBM is currently under consideration as a target for ...
Kaprealian, Tania, Lee, Mi-Heon, McBride, William H, Nesseler, Jean Philippe, Nickers, Philippe, Niclou, Simone P, Schaue, Dorthe   +6 more
core  

Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer

Cost Effectiveness and Resource Allocation
Background Programmed cell death protein 1 (PD-1) monoclonal antibody, pembrolizumab, is a promising drug for platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (NPC).
Jing Nie, Huina Wu, Qian Wu, Lihui Liu, Ke Tang, Shuo Wang, Jiyong Wu   +6 more
doaj   +1 more source